AT13387 is a non-geldanamycin inhibitor of HSP90, it inhibited the proliferation of imatinib-sensitive (GIST882, GIST-T1) and -resistant (GIST430, GIST48) cell lines, including those resistant to the geldanamycin analogue HSP90 inhibitor, 17-AAG. AT13387 showed a median EC(50) value of 41 nM and exhibited activity consistent with a cytotoxic effect in vitro. In vivo, antitumor activity of AT13387 was showed in both the imatinib-sensitive, GIST-PSW, xenograft model and a newly characterized imatinib-resistant, GIST430, xenograft model. AT13387 has shown activity against a wide array of tumor cell lines, including lung cancer cell lines. While AT13387 was rapidly cleared from blood, its retention in tumor xenografts was markedly extended, and it was efficacious in a range of xenograft models. A combination of AT13387 and imatinib treatment in the imatinib-resistant GIST430 model significantly enhanced tumor growth inhibition over either of the monotherapies.
|Cell lines||HCT116, A549, MCF-7, U266, PANC1, Huh-7, DU145, MES-SA, SKOV3, HL60, A375 and TFK-1 cells line|
|Preparation method||Proliferation assays.
Cells were seeded into 96-well plates before the addition of compound in 0.1% (v/v) DMSO. GI50 were determined using a 10-point dose response curve for three cell doubling times. After compound incubation 10% (v/v), Alamar blue (Biosource International, Camarillo, CA, USA) was added, and cells were incubated for a further 4 h. Fluorescence was read at λex = 535 nm and λem = 590 nm.
|Concentrations||0~1 μ M|
|Incubation time||48 or 72 h|
|Animal models||Athymic mice bearing NCI-H1975 xenografts|
|Formulation||17.5% (w/v) hydroxypropyl-β-cyclodextrin|
|Dosages||70 mg/kg on days 1, 4, 8, 12 and 16; 55 mg/kg on days 1, 4, 8, 12 and 16; or 90 mg/kg on days 1, 8 and 16.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 25 mg/mL|
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T, et al. Mol Cancer Ther. 2012 Aug;11(8):1799-808. PMID: 22714264.
The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Graham B, et al. Cancer Sci. 2012 Mar;103(3):522-7. PMID: 22181674.
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
Kang MH, et al. Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8. PMID: 21538821.
|Related HSP90 Products|
Teprenone(Geranylgeranylacetone; GGA)is commonly utilized to protect the gastric mucosa in peptic ulcer disease; has been shown to protect the myocardium from ischemia/reperfusion by activating heat shock proteins.
Celastrol is a potent antioxidant and anti-inflammatory agent and a novel HSP90 inhibitor.
CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.
Retaspimycin is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90).
KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.